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PREFACE
The Occupational Safety and Health Act of 1970 emphasizes the need 
for standards to protect the health and safety of workers exposed to an 
ever-increasing number of potential hazards in their workplace.
Pursuant to the fulfillment of this need, the National Institute for 
Occupational Safety and Health (NIOSH) has developed a reporting 
strategy intended to assist employers in providing personal protection 
for employees from exposure to carcinogenic, mutagenic, and teratogenic 
substances. This strategy involves the development of Special 
Occupational Hazard Reviews which serve to support and complement the 
other major criteria documentation activities of the Institute. It is 
the intent of a Special Occupational Hazard Review to document, from a 
health standpoint, the problems associated with a given industrial 
chemical or process. While Special Occupational Hazard Reviews are not 
intended to supplant the more comprehensive NIOSH Criteria Documents 
nor the less comprehensive NIOSH Current Intelligence Bulletins, they 
are nevertheless prepared in such a way as to be amenable to full 
regulatory usage if so desired. Dissemination of Special Occupational 
Hazard Reviews may be accomplished through appropriate trade 
associations, unions, industries, and members of the scientific 
community.
J. Michael Lane, M.D.
Acting Director, National Institute 
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I. INTRODUCTION
4,4'-Methylenebis(2-chloroaniline), more commonly referred to as 
MOCA, a registered trade name of the DuPont Company, has the formula 
C13H12C12N2. It has a molecular weight of 267.16. A yellow to light 
gray-tan, nearly odorless, crystalline solid, 4,4'-Methylenebis(2- 
chloroaniline) has a specific gravity of 1.44 at 24 C and a melting 
range of 100-110 C. Its vapor pressure is very low, i.e., less than 
0.00001 mmHg at 25 C, and 0.000036 mmHg at 100 C. It is only slightly 
soluble in water, but is soluble in alcohol, ether, ketones, esters, 
organic solvents (e.g., trichloroethylene and toluene), and .in lipids. 
4,4'-Methylenebis(2-chloroaniline) is a weak base having the general 
chemical characteristics of primary aromatic amines. Synonyms for this 
compound include: 4,4'-methylene-bis(2-benzenamine); diamino-3- 
chlorophenylmethane; bisamine; di-(4-amino-3-chlorophenyl)methane;
4,4'-diamino-3,3'-dichlorodiphenylmethane; 3,3'-dichloro-4,4'- 
diaminodiphenylmethane; methylenebis(ortho-chloroaniline); and p,p'- 
methylenebis(ortho-chloroaniline). Common or trade names include:
4,4'-Methylenebis(2-chloroaniline); DACPM; MBOCA; MOCA; MCA; Curaline 
M; Curene 442; and Cyanaset (1,2).
It is commercially important as a curing agent for diisocyanate- 
based polymers (polyurethanes) and epoxy resin systems used in the 
manufacture of certain products, particularly integral-skin 
polyurethane semi-rigid foam as used for crash padding, and solid 
urethane rubber moldings such as gear hlanks and industrial tires.
4,4'-Methylenebis(2-chloroaniline) is used to vary the hardness,
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flexibility, and impact strength of these products. The first U.S. 
commercial production of 4,4'-Methylenebis(2-chloroaniline) is believed 
to have begun in 1956, using a process based on the reaction of 
formaldehyde and ortho-chloroaniline. Commercial-grade 4,4'- 
Methylenebis(2-chloroaniline) is available in the form of pellets or 
granules, and in a premixed compound with polyhydric alcohols 
(polyols). During the melting of solid 4,4'-Methylenebis(2- 
chloroaniline), when temperatures of about 200 C are used, the release 
of irritant and toxic vapors (primarily ortho-chloroaniline) may occur 
(1 ,2).
NIOSH estimated through a national survey that in the early 1970's 
approximately 55,000 U.S. workers were potentially exposed to 4,4'- 
Methylenebis(2-chloroaniline) (3). The majority of these workers were 
employed in small-to-medium sized establishments where occupational 
health services may not have been readily available.
Based on information presented by NIOSH (Appendix I), 4,4'- 
Methylenebis(2-chloroaniline) was one of .14 substances for which the 
Occupational Safety and Health Administration (OSHA) promulgated an 
emergency temporary standard on May 3, 1973. Final, individual 
standards for these substances were promulgated by OSHA on January 29, 
1974. (4) On December 17, 1974, the standard for 4 , 4 '-Methylenebis(2- 
chloroaniline) was remanded for procedural reasons by the 3rd Circuit 
Court of the U.S. Court of Appeals (Synthetic Organic Chemicals 
Manufacturer's Association vs. Brennen 506.F2d 385 1974). Subsequent 
to the court decision, the standard was deleted from the Code of 
Federal Regulations. Even though not enforceable as a Federal
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standard, several states, including California, continued to enforce 
the standard under state law. The California Department of Health has 
recently held hearings to consider promulgation of environmental 
exposure limits for 4,4'-Methylenebis(2-chloroaniline).
In 1972, the American Conference of Governmental Industrial 
Hygienists (ACGIH) included 4,4'-Methylenebis(2-chloroanaline) as an 
experimental carcinogen in Appendix A of its Threshold Limit Values 
booklet (5) without a recommended environmental limit. The 
experimental carcinogen designation was applied by the ACGIH to 
industrial substances found to be of high potency for inducing tumors 
under experimental conditions in animals. In 1975, the ACGIH revised 
their designation for experimental carcinogens to be "Occupational 
Substances Suspected of Oncogenic Potential for Workers" and assigned 
4,4'-Methylenebis(2-chloroaniline) a threshold limit value of 0.02 ppm 
with a skin notation. The documentation for this TLV was apparently 
not based on a consideration of the carcinogenic potential of this 
chemical but was established with the belief that this limit was 
"sufficiently low as to prevent systemic poisioning, provided skin 
contact is avoided." (6 ). The documentation included a warning that 
worker exposure by all routes should be reduced to a minimum in light 
of the warning of the potency for the chemical to induce tumors in 
animals (7). In 1974, the International Agency for Research on Cancer 
reviewed the information concerning 4,4'-Methylenebis(2- 
chloroaniline)'s potential carcinogenicity (1 ).
Additional information to that which appeared in the above sources 
is currently available. The following section provides a brief review
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of the information available in 1973 (Appendix I), and a more detailed 
presentation of recent studies along with recommendations for control 
of workplace exposures to 4,4'-Methylenebis(2-chloroaniline).
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II. HAZARD INFORMATION UPDATE
4,4'-Methylenebis(2-chloroaniline) was found to be "moderately 
toxic" when administered orally in single doses to male rats, with an 
Approximate Lethal Dose (ALD) of 1,000 mg/kg, (8 ). The report 
indicated that 4,4'-Methylenebis(2-chloroaniline) affected the kidneys 
of the experimental animals, and interfered with the hemopoietic 
system, as evidenced by the formation of methemoglobin and formation of 
red blood cells at sites other than the bone marrow. The clinical 
signs of toxicity at lethal doses included rapid and irregular 
respiration (eventually becoming labored), pallor, cyanosis, weakness, 
polyuria, and coma. Repeated sublethal oral doses (200 mg/kg) in the 
rat produced pallor, slight cyanosis, and a depressed rate of weight 
gain during treatment.
In a separate report (9) submitted from the same laboratory, the 
oral LD50 for 4,4'-Methylenebis(2-chloroaniline) (as a 10% solution in 
acetone (15)/peanut oil (85)) in male rats was reported as 750 mg/kg, 
with gross pathological changes including congested kidneys, an 
enlarged spleen, and hemorrhagic serosa of the stomach found in a few 
select animals.
Single 40 mg/kg doses of 4, 4 '-Methylenebis(2-chloroaniline) 
produced marked methemoglobinemia in dogs (10)_. The methemoglobin 
level returned nearly to normal 24 hours after the single dose. When 
administered daily in gradually increasing doses a slight 
methemoglobinemia and a macrocytic anemia developed, accompanied by 
fecal excretion of urobilinogen. The study also identified a major 
metabolite of 4,4'-Methylenebis(2-chloroaniline) in the dog urine,
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5-hydroxy-3,3'-dichloro-4,4'-bis-aminodiphenylmethane. Clinical signs 
noted were weakness, vomiting, pallor and cyanosis.
Skin absorption studies on rabbits showed the ALD by this route to 
be greater than 5 g/kg, with pallor and weight loss observed (10). 
Repeated applications of 2.2 g/kg to the skin of rabbits resulted in 
pallor, cyanosis and hematuria during the 1 st week of treatment only.
No significant hematologic changes were found. Skin tests with guinea 
pigs indicated the compound to be mildly irritating, and not to produce 
allergic contact dermatitis (8 ).
An interim report of an 18-month feeding study conducted in NIOSH 
laboratories (11) confirmed the earlier reports reviewed in the 1973 
NIOSH Hazard Review (Appendix I) that 4,4'-Methylenebis(2- 
chloroanlline) caused pulmonary and mammary gland adenocarcinomas, 
hepatocellular carcinomas, Zymbal gland tumors and hemangiosarcomas in 
male rats. 4,4'-Methylenebis(2-chloroaniline) was fed in graded doses 
in two different diets to male rats for 18 months; 250, 500, and 1,000 
ppm in protein adequate (27% casein) and .125, 250, 500 ppm in protein 
deficient (8 % casein). Groups of male rats which were fed the same two 
diets, but without 4, 4 '-Methylenebis(2-chloroaniline), served as 
controls. All surviving animals were killed 24 months after initiation 
of the chemical feeding. All animals that were started on the 
experiment were necropsied, including those that died during the 
experiment or were killed in a moribund state, as well as those killed 
at 24 months. A statistically increased incidence of the following 
types of tumors were observed in the 4, 4 '-Methylenebis(2-chloroaniline) 
treated animals regardless of the protein content of their diet:
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adenocarcinoma of the lungs, hepatocellular carcinoma, mammary gland 
adenocarcinoma, and Zymbal gland tumors. There was a definite dose- 
response relationship, the larger the dose the greater the incidence of 
tumors. This interim report demonstrates that the effect of diet alone 
could not account for the carcinogenic activity of 4,4'-Methylenebis(2- 
chloroaniline).
The lowest concentration shown to produce all of the above tumor 
types in the protein adequate group was also the lowest concentration 
tested in that group, 250 ppm of 4,4'-Methylenebis(2-chloroaniline).
The lowest concentration shown to produce pulmonary and mammary gland 
adenocarcinomas in the protein deficient group was 125 ppm of 4,4'- 
Methylenebis(2-chloroaniline) in the diet, again the lowest 
concentration tested in that group. The increased incidence of lung 
neoplasms in this group was statistically significant (6 / 1 0 0  vs.
0/100). The authors concluded that "In both diet groups the lungs were 
the most sensitive organs to the induction of neoplasms by 4,4’- 
Methylenebis(2-chloroaniline)
In comparing the animals that received 500 ppm of 4,4*- 
Methylenebis(2 -chloroaniline) in the protein deficient and protein 
adequate groups, the investigators concluded that protein deficiency 
caused an increased incidence of hepatocellular carcinomas. However, 
there was a lower incidence of mammary gland and lung adenocarcinomas 
in the protein deficient group as compared to the protein adequate 
group.
There was an increased incidence of hemangiosarcomas in the protein 
deficient group, 22% (4/18) in the 500 ppm group vs. 2% (1/49) in the
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controls when comparisons were made between only those treated animals 
alive at the time the hemangiosarcomas were first diagnosed. The 
Fisher Exact Test yields a P value of 0.0164 (i.e., significant at the 
0.05 level). The most current information, as yet unpublished, 
indicates the lifetime incidence rates to be 8 % (4/50) in the treated, 
protein deficient group, and 1% (1/100) in the controls. The Fisher 
Exact Test yields a P value of 0.0425 (i.e., significant at the 0.05 
level).
Another objective of the study was to determine whether or not the 
treated animals with tumors had more 4,4'-Methylenebis(2-chloroaniline) 
in their urine than the treated animals without tumors. The results 
were not consistent. There were significantly higher levels of 4,4'- 
Methylenebis(2-chloroaniline) (P less than 0.05) in the urine of 
animals with tumors in the 500-ppm dosage groups, regardless of diet, 
than in those animals in the same dosage groups without tumors. In the 
protein adequate, 500-ppm group, animals with tumors had a mean of 0.79 
ppm in the urine after acid hydrolysis, while those without tumors had
0.50 ppm. In the protein deficient, 500-ppm group, the respective 
values were 2.19 ppm and 1.12 ppm. However, there were no 
statistically significant differences between similar groups at the 
other concentrations of 4,4'-Methylenebis(2-chloroaniline) tested. The 
urine was collected and analyzed 75-76 weeks after initiating the 
exposures and just before exposure was discontinued.
At the lowest concentration tested, 125 ppm, the mean concentration 
in the urine before acid hydrolysis was 0.09 ppm, and 0.63 ppm after 
acid hydrolysis. Although the significance of the observation is not 
known, it is interesting to note that equal or higher levels of
4,4'-Methylenebis(2-chloroaniline) have been reported in the urine of 
exposed workers (15, 16).
In work performed at Haskell Laboratory, urinary bladder tumors 
were produced in dogs given 4,4'-Methylenebis(2-chloroaniline) orally 
(12). Six female beagle dogs were given an oral dose of 100 mg by 
capsule, 3 days per week for the first 6 weeks, and then 5 days per 
week continuously for periods up to 9 years. The dose varied from 8 to 
15 mg/kg body weight per day among the dogs. Six untreated female 
beagle dogs were used as controls. The test was terminated after 9 
years of treatment, at which time all animals were killed and 
necropsied. The average plasma glutamic-pyruvic transaminase activity 
of the dogs fed 4,4'-Methylenebis(2-chloroaniline) was found to be 
higher than that of the controls during the 1 st and last 2 years on 
test. During the 8 th and 9th years, the urine sediment from the dogs 
given 4,4'-Methylenebis(2-chloroaniline) contained excessive numbers of 
erythrocytes, leukocytes, and epithelial cells. Some epithelial cells 
exhibited abnormalities that suggested neoplasia in the genitourinary 
tract. One treated animal died after 3.4 years from complications 
which were not considered by the investigators to be related to the 
test compound. One treated animal, killed after 8.3 years, had a 
papillary transitional cell carcinoma of the urinary bladder. The 
remaining four animals were killed after 9 years. Three of these had 
papillary transition cell carcinomas of the urinary bladder, and one 
had both a transitional cell carcinoman and an adenocarcinoma of the 
urethra. The urethral tumor had metastasized to the liver, but the 
papillary transitional cell carcinomas found in the other four dogs had
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not invaded the muscle layers of the bladder wall, and had not 
metastasized. Since no urinary bladder tumors were found in the six 
control dogs, 4,4'-Methylenebis(2-chloroaniline) was judged to be 
carcinogenic for the urinary bladder of dogs under the conditions 
employed (P less than 0.025, Fisher’s Exact Test, one tail). Three of 
five treated dogs contained hyperplastic nodules in the liver, with no 
such nodules in the six control dogs (P greater than 0.05, Fisher's 
Exact Test, one tail). This was considered by the investigators to be 
suggestive of an effect of 4 , 4 '-Methylenebis(2-chloroaniline) 
treatment.
4,4'-Methylenebis(2-chloroaniline) has also been shown to be 
mutagenic in in vitro experiments. McCann et al, (13) reported 2.7 
revertants per nmol (1050 revertants/plate) in the "Ames" test which 
utilizes Salmonella typhimurium as the test organism.
In approximately 22 years of industrial experience with the 
manufacture of 4,4'-Methylenebis(2-chloroaniline), DuPont has found no 
evidence of a carcinogenic effect in its workers (14) . This is the 
only documentation of 4,4'-Methylenebis(2-chloroaniline)'s carcinogenic 
potential based on human experience which was found in the literature. 
It is noted in the report that the group studied was small, and that 
the length of time for which the workers were exposed to 4,4'- 
Methylenebis(2-chloroaniline) was too short to "permit statistically 
significant conclusions."
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III. SUMMARY AND CONCLUSIONS
From the toxicologic information presented in APPENDIX I and the 
preceding information update, a profile of 4,4'-Methylenebis(2- 
chloroaniline)'s potentially hazardous properties can be developed.
4,4'-Methylenebis(2-chloroaniline) possesses the general toxicity 
characteristics of aromatic amines, and may, if introduced into the 
human body, produce cyanosis from methemoglobin formation (2). From an 
occupational health standpoint, there is greater concern for 4,4'- 
Methylenebis(2-chloroaniline)’s carcinogenic potential, evidence for 
which comes primarily from animal bioassays as well as in vitro 
mutagenicity studies. Results reported by five independent groups of 
investigators clearly demonstrate 4, 4 ,-Methylenebis(2-chloroaniline) to 
be oncogenic in the rat, mouse, and dog. Ingestion of daily doses of 
4,4’-Methylenebis(2-chloroaniline) by mice and rats has resulted in the 
appearance of cancers of the liver, kidneys, lungs, skin, and mammary 
glands (11, Appendix I). Subcutaneous injection of 4,4'- 
Methylenebis(2-chloroaniline) in rats produced liver and lung cancer in 
both sexes (Appendix I ) . Urinary bladder cancer was produced in female 
beagle dogs fed doses of 4,4'-Methylenebis(2-chloroaniline) which 
varied from 8 to 15 mg/kg body weight per day for up to 9 years (12). 
Further, 4,4,-Methylenebis(2-chloroaniline) is mutagenic in in vitro 
tests utilizing Salmonella bacteria (13).
Based on positive oncogenic results in three animal test species, 
NIOSH recommends that 4,4’-Methylenehis(2-chloroaniline) he treated as 
a potential occupational carcinogen. Because a significant route of
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entry into the body is by skin absorption (1, 7, 15), efforts must be 
made to prevent skin contact with 4,4’-Methylenebis(2-chloroaniline), 
whenever possible. The use of protective clothing made of butyl 
rubber, neoprene, or spunbonded olefin has been shown to assist in the 
reduction of worker exposure through skin contact (14, 17).
Although research information is not yet available to demonstrate a 
quantitative relationship between skin absorption of 4,4'- 
Methylenebis(2-chloroaniline) and urinary levels in workers, industrial 
experience indicates that urinary monitoring is necessary as an adjunct 
to the monitoring of airborne 4,4’-Methylenebis(2-chloroaniline) in 
order to detect worker exposure as a result of absorption through the 
skin (15). The finding of 4,4’-Methylenebis(2-chloroaniline) in the 
urine demonstrates that exposure has occurred and can indicate work 
situations which need additional control efforts. Likewise, monitoring 
of workplace surfaces can identify where contamination problems exist 
and where the potential for workplace exposure is greatest. Details of 
one company's method of analysis for 4,4'-Methylenebis(2-chloroaniline) 
in urine are given in Appendix III. Detailed procedures for monitoring 
work surfaces for 4,4'-Methylenebis(2-chloroaniline) contamination are 
presented in reference 18 and in Appendix IV.
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IV. CONTROL GUIDELINES
The National Institute for Occupational Safety and Health 
recommends that employee exposure to 4, 4 '-Methylenebis(2-chloroaniline) 
(MOCA) in the workplace, be controlled so that no worker will be 
exposed at concentrations in excess of 3 micrograms per cubic meter 
(/ig/cu m) of air determined as a time-weighted average (TWA) 
concentration for up to a 10-hour workshift, 40 hour workweek, over a 
working lifetime. The recommended exposure level of 3 jug/cu m  is the 
lowest level at which 4,4'-Methylenebis(2-chloroaniline) can be 
reliably measured at this time. The control guidelines contain 
recommendations for medical surveillance, informing employees of 
hazards, sanitation, work practices, labeling and posting, personal 
protective clothing and equipment, monitoring and recordkeeping.
While compliance with these recommendations should materially 
reduce the risk of developing cancer from 4,4'-Methylenebis(2- 
chloroaniline), no absolutely safe concentration can be established for 
a Carcinogen at this time. The employer should regard the recommended 
permissible exposure level as the upper boundary of exposure, and make 
every effort to keep exposure by all routes as low as possible.
"Occupational exposure to 4,4’-Methylenebis(2-chloroaniline)" 
refers to any workplace situation in which it is manufactured, 
processed, used, or stored. Since 4 , 4 '-Methylenebis(2-chloroaniline) 
is readily absorbed through the skin, all skin contact with it must be 
prevented.
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Section 1 - Permissible Exposure Level
(a) Concentration
4,4' Methylenebis(2-chloroaniline) shall be controlled in the 
workplace so that the concentration of airborne 4,4'-Methylenebis(2 - 
chloroaniline), does not exceed 3 /ng/cu m in breathing zone air 
determined as a time-weighted average (TWA) concentration.
(b) Sampling and Analysis
The recommended environmental level represents the lowest 
concentration of 4,4'-Methylenebis(2-chloroaniline) reliably measurable 
by the recommended sampling and analytical methods selected.
Procedures for the collection and analysis of air samples shall be as 
provided in Appendix II, or by any method at least equivalent in 
accuracy, precision, and sensitivity to the method specified.
Section 2 - Medical
Medical surveillance shall be made available to employees as 
outlined below:
(a) Preplacement
Preplacement examinations shall be made available to all workers 
occupationally exposed to 4,4'-Methylenebis(2-chloroaniline).
History and physical testing shall direct emphasis towards, but not 
be limited to, the pulmonary, renal, and hepatic systems, and shall 
include the personal and occupational history of the employee and 
family including genetic and environmental factors. Additionally, such 
factors as the current systems review, pregnancy, current treatment
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with steroids or cytotoxic agents, and smoking habits should be 
considered.
(b) Laboratory and Other Special Tests
(1) 14" x 17" chest X-Ray
(2) Laboratory examinations to include:
Complete Blood Count;
Blood Chemistry tests to include serum glutamic oxalacetic 
transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), 
alkaline phosphatase, total bilirubin, and gamma-glutamyl 
transpeptidase (GGTP);
Complete urinalysis to include microscopic examination and 
cytologic examination for neoplastic cells. Monitoring of urinary 
4,4'-Methylenebis(2-chloroaniline) content is an important adjunct 
to the monitoring of airborne 4,4'-Methylenebis(2-chloroaniline) 
for the detection of worker exposure.
Additional tests such as sputum cytology may be considered by the 
examining physician.
Referral to appropriate medical specialists shall he considered 
if abnormalities are demonstrated by the above examinations or tests.
(c) Periodic examinations shall be made available on at least an 
annual basis and shall consist of those procedures listed in 2 (a) and
(b) above.
(d) If the worker being examined has been employed directly in 
4,4'Methylenebis(2-chloroaniline) production or handling for 10 years 
or longer, the laboratory portions of the above shall be repeated every 
6 months. These examinations shall also be provided more frequently
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if, in the opinion of the responsible physician, a worker shows 
abnormalities in the tests that warrant further evaluation.
(e) Pertinent medical records shall be maintained for all employees 
occupationally exposed to 4,4T-Methylenebis(2-chloroaniline) in the 
workplace. Such records shall be maintained for at least 30 years 
after termination of employment. These records shall be made available 
to the designated medical representatives of the Secretary of Health, 
Education, and Welfare, of the Secretary of Labor, of the employer, the 
employee, or former employee.
Section 3 - Labeling and Posting
A  label shall be placed on each shipping and storage container of 
4,4'-Methylenebis(2-chloroaniline), and all areas where there is 
occupational exposure to 4,4’-Methylenebis(2-chloroaniline) shall be 
posted.
All warning signs shall be printed both in English and in the 
predominant language of non-English-reading workers. Workers unable to 
read the labels and signs provided shall be informed verbally about 
hazardous areas and the instructions printed on labels and signs.
(a) Labeling




(Trademark, Common Name, or Chemical Name)
WARNING!I
SUSPECT CANCER AGENT 
DANGEROUS TO HEALTH IF INHALED OR SWALLOWED 
Keep containers closed when not in use.
Wash thoroughly before eating, drinking, smoking, or using toilet.
AVOID SKIN CONTACT
(b) Posting
Entrances to areas where there is occupational exposure to 4,4'- 
Methylenebis(2-chloroaniline) shall be posted with signs bearing the 
legend:
CANCER SUSPECT AGENT 
AUTHORIZED PERSONNEL ONLY
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If respiratory protection is required in accordance with Section 4, 
the following statement in large letters shall be added to the required 
sign:
RESPIRATORY PROTECTION REQUIRED IN THIS AREA
Section 4 - Personal Protective Equipment and Clothing
(a) Respiratory Protection
(1) Engineering controls shall be used wherever needed to keep 
airborne 4,4'-Methylenebis(2-chloroaniline) concentrations below the 
recommended permissible exposure level. Compliance with this level may 
be achieved by the use of respirators under the following conditions 
only:
(A) During the time necessary to develop, install or test 
the required engineering controls or when such controls fail.
(B) For nonroutine operations, such as emergency 
maintenance or repair activities.
(C) During emergencies when air concentrations of 4,4'- 
Methylenebis(2-chloroanilineX may exceed the recommended permissible 
exposure level.
(2) When a respirator is permitted by paragraph (a)(1) of this 
section, it shall be selected and used pursuant to the following 
requirements:
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(A) The employer shall ensure that no employee Is exposed 
to 4,4'-Methylenebis(2-chloroaniline) because of Improper respirator 
selection, fit, use, or maintenance.
(B) The employer shall establish and enforce a respirator 
program meeting the requirements of 29 CFR 1910.134 as amended.
(C) The employer shall provide respirators in accordance 
with Table 1-1, and shall ensure that the employee uses the respirator 
provided when necessary.
(D) Respiratory protective devices described in Table 1-1 
shall be those approved under the provisions of 30 CFR 11.
(E) The employer shall ensure that respirators are 
adequately cleaned and maintained, and that employees are instructed 
and drilled, at least annually, in the proper use and testing for 
leakage of respirators assigned to them.
(F) Respirators shall be easily accessible and employees 




Concentration of Respirator Type Approved under
4,4'-Methylenebis(2-chloroaniline) Provisions of 30 CFR II
Greater than 3 jug/cu m, or (I)
Emergency (entry into areas of 
unknown concentration for 
emergency purposes)
Self-contained breathing apparatus 
with full facepiece operated in pressure' 
demand or other positive pressure mode.
(2) Combination Type C supplied-air
respirator with full facepiece operated 
in pressure-demand mode and auxiliary 
self-contained air supply.
(b) Eye protection
Eye protection shall be provided by the employer and used by the 
employees where eye contact with 4,4f-Methylenebis(2-chloroaniline) is 
likely. Selection, use, and maintenance of eye protective equipment 
shall be in accordance with the provisions of the American National 
Standard Practice for Occupational and Educational Eye and Face
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Protection, ANSI Z87.1-1968. Unless eye protection is afforded by a 
respirator hood or facepiece, protective goggles (splash-proof safety 
goggles or cup-cover type dust and splash safety goggles) that comply 
with 29 CFR 1910.133(a)(2)-(a)(6)), or a face shield (8 -inch minimum) 
shall be worn at operations where there is danger of eye contact with 
4,4'-Methylenebis(2-chloroaniline) because of spills or splashes. If 
there is danger of 4,4,-Methylenebis(2-chloroaniline) striking the eyes 
from underneath or around the sides of the face shield, safety goggles 
shall be worn as added protection.
(c) Protective Clothing
Protective clothing shall be resistant to the penetration and to 
the chemical action of 4,4'-Methylenebis(2-chloroaniline). Clothing 
made of butyl rubber, neoprene, spunbonded olefin, or an equally 
effective material are suggested at this time. Protective clothing 
including gloves, bib-type aprons, boots, and overshoes, shall be 
provided for, and worn by, each employee during any operation that may 
cause direct contact with 4, 4 '-Methylenebis(2-chloroaniline). 
Supplied-air hoods or suits resistant to penetration by 4,4'- 
Methylenebis(2 -chloroaniline) shall be worn when entering confined 
spaces, such as pits or storage tanks. In situations where heat stress 
is likely to occur, supplied-air suits, preferably cooled, are 
recommended. The employer shall ensure that all personal protective 
clothing is inspected regularly for defects, and is maintained in a 
clean and satisfactory condition.
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Section 5 - Informing Employees of Hazards from 
4,4* Methylenebis(2-chloroaniline)
(a) All new and present employees working where occupational 
exposure to 4,4’-Methylenebis(2-chloroaniline) may occur shall be 
informed orally and in writing of the hazards, appropriate emergency 
procedures, and proper conditions and precautions concerning its safe 
use and handling.
(b) Employers shall institute a continuing education program to 
ensure that all employees have current knowledge of job hazards, 
cleanup methods, maintenance, emergency and evacuation procedures.
This program shall be held for all employees with occupational exposure 
to 4,4'-Methylenebis(2-chloroaniline) at intervals not greater than 
quarterly, or whenever there is a process change.
Section 6 - Work Practices
(a) Emergency Procedures
For all work areas where emergencies may occur, the employer shall 
ensure that employees are instructed in and follow the procedures 
specified below and any others appropriate to the specific operation or 
process.
(1) Procedures shall include at least prearranged plans for 
reentry into areas where 4,4'-Methylenebis(2-chloroaniline) leaks or 
spills have occurred for cleanup, decontamination, or maintenance 
purposes.
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(2) Evacuation alarm systems shall be provided by the
employer.
(3) Nonessential employees shall be evacuated from hazardous 
areas during emergencies. Perimeters of these areas shall be 
delineated, posted, and secured. Employees in adjacent areas shall be 
trained in evacuation procedures should these work areas become 
invloved.
(4) Only personnel trained in the emergency procedures and 
protected against the attendant hazards (by personal protective 
equipment and clothing as specified in Section 4) shall shut off 
sources of 4,4'-Methylenebis(2-chloroaniline), clean up spills, control 
and repair leaks, and fight fires in 4,4’-Methylenebis(2-chloroaniline) 
work areas. Proper protective respirators and clothing shall be worn 
by all personnel in the hazard area until concentrations of airborne
4,4,-Methylenebis(2-chloroaniline) have been demonstrated by monitoring 
to be below the recommended permissible exposure level.
(5) Firefighting procedures shall be established for areas 
where flammable materials are used with 4,4'-Methylenebis(2 - 
chloroaniline). Chemical foam, carbon dioxide, or dry chemicals shall 
be used for firefighting in areas where 4,4'-Methylenebis(2- 
chloroaniline) is present.
(6 ) Showers, eyewash fountains, and washroom facilities shall 
be provided and so located as to be readily accessible to workers in 
all areas where skin or eye contact with 4,4'-Methylenebis(2 - 
chloroaniline) is likely. If 4,4'-Methylenebis(2-chloroaniline) comes 
into contact with clothing or skin, contaminated clothing shall be
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promptly removed and the skin washed thoroughly with soap and water.
If 4,4'-Methylenebis(2-chloroaniline) gets into the eyes, the eyes 
shall be flushed immediately with copious quantities of water.
(7) Medical attention shall be provided for any workers 
involved in an emergency situation. Such exposures shall be reported 
to the immediate supervisor by the affected worker or a fellow 
employee.
(b) Control of Airborne 4,4'-Methylenebis(2-chloroaniline).
(1) Suitable engineering controls designed to limit exposure 
to 4,4’-Methylenebis(2-chloroaniline) to that prescribed in Section 
1 (a) shall be used.
The use of completely enclosed processes is the recommended method 
of control for 4,4'-Methylenebis(2-chloroaniline). Local exhaust 
ventilation may also be effective when used alone or in combination 
with process enclosure. When a local exhaust ventilation system is 
used, it shall be designed to prevent the accumulation or recirculation 
of ventilation control or process air in the workroom, to maintain 
4,4'-Methylenebis(2-chloroaniline) concentrations below the permissible 
exposure level and to remove it from the breathing zone of employees. 
Exhaust systems discharging into outside air must conform with 
applicable local, state, and Federal air pollution regulations. 
Ventilation systems shall be subjected to regular preventive 
maintenance and cleaning to ensure effectiveness, which shall be 
verified by periodic airflow measurements at least quarterly. 
Measurements of system efficiency shall also be made immediately by 
personnel properly attired in specified protective equipment when any
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change in production, process, or control might result in increased 
concentrations of airborne 4,4'-Methylenebis(2-chloroaniline).
Tempered makeup air shall be provided to work areas in which exhaust 
ventilation is operating.
(2) In operations where premixed forms of 4,4'- 
Methylenebis(2-chloroaniline) can be substituted for other forms of 
this chemical or where these premixed forms would reduce the degree of 
worker exposure, such subsitution should be made.
(c) Handling of 4,4'-Methylenebis(2-chloroaniline), and Related Work 
Practices.
(1) Written operating procedures shall be developed and posted 
wherever 4,4'-Methylenebis(2-chloroaniline) is processed, handled, 
used, or stored.
(2) The employer shall ensure that safety showers, eyewash 
fountains, and other emergency equipment are in proper working order 
through regularly scheduled inspections performed by qualified 
maintenance personnel.
(3) Operating systems shall be inspected daily for signs of 
leaks by personnel attired in protective equipment (as specified in 
Section 4). All equipment, including valves, fittings, and 
connections, shall be checked for tightness and good working order.
All newly made connections shall be checked for leaks by trained 
personnel attired in the prescribed personel protective equipment 
immediately after the system is placed in operation.
(4) If a leak occurs, it shall be corrected immediately. Work 
shall resume normally only after necessary repair or replacement has
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been completed, the area has been ventilated, and the concentration of 
4,4'-Methylenebis(2-chloroaniline) has been determined by monitoring to 
be below the permissible exposure level.
(5) Transportation and use of 4, 4 '-Methylenebis(2- 
chloroaniline) shall comply with all applicable local, state, and 
Federal regulations.
(6 ) When 4 , 4 '-Methylenebis(2-chloroaniline) containers are 
being moved, or when they are not in use, appropriate covers shall be 
in place. Such containers shall be moved only with the proper 
equipment, and secured to prevent dropping or loss of control while 
moving.
(7) Process valves and fittings shall be readily accessible, 
and should not be located in pits and congested areas.
(8 ) Containers and systems shall be handled and opened with 
care. Approved protective equipment (as specified in Section 4) shall 
be worn while opening, connecting, and disconnecting 4,4'- 
Methylenebis(2-chloroaniline) containers and systems. Adequate 
ventilation shall be made available to prevent exposure of workers to 
4,4'-Methylenebis(2-chloroaniline) when opening containers and systems.
(9) Personnel shall work in teams when 4,4'-Methylenebis(2- 
chloroaniline) in a quantity sufficient enough to create a hazard is 
first admitted to a system, while repairing leaks, or when entering a 
confined or enclosed space.
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(d) Work Areas
(1) Regulated areas shall be established and access limited to 
authorized personnel where there is occupational exposure to 4,4'- 
Methylenebis(2 -chloroaniline).
(e) Storage
(1) Storage facilities shall be designed to contain spills 
completely, and to prevent contamination of the workroom environment.
(2) Storage of 4,4'-Methylenebis(2-chloroaniline) in the same 
area with reactive metals, such as aluminum or magnesium, or other 
reactive chemicals, such as liquid ammonia, shall be prohibited.
(3) Storage containers shall be periodically inspected for
leakage.
(4) Ventilation switches and emergency respiratory equipment 
shall be located outside storage areas in readily accessible locations 
that will be free of 4,4'-Methylenebis(2-chloroaniline) should an 
emergency occur.
(f) Spills, Leaks, and Waste Disposal
(1) If a leak or spill occurs, the following steps shall be
taken:
(A) Evacuate all nonessential personnel from the area.
(B) Adequately ventilate the area where the spill or leak
occurs.
(C) If in molten form, allow to crystallize; break up 
crystallized material and mechanically sweep up for disposal.
(D) If in solid form, collect spilled material (as above) 
for reclamation or disposal.
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(2) Personnel entering the spill or leak area shall be 
furnished with appropriate personal protective equipment. All other 
personnel shall be excluded from the area.
(3) All wastes and residues containing 4, 4 '-Methylenebis(2- 
chloroaniline) shall be collected in 4,4’-Methylenebis(2 -chloroaniline) 
resistant containers, and incinerated or buried in such a manner that 
no 4,4'-Methylenebis(2-chloroaniline) or toxic decomposition products 
are released into the environment.
(4) All workplace surfaces including process equipment shall be 
washed down with soap and water or an effective solvent on a periodic 
basis, the frequency of this periodic washdown shall be increased as 
indicated by the results of urinary monitoring and spot tests for work 
surface contamination. At no time shall the visible accumulation of 
4,4'-Methylenebis(2-chioroaniline) be allowed.
Section 7 - Sanitation Practices
(a) Plant sanitation shall meet the requirements of 20 CFR 1910.141.
(b) Workers shall change into work clothing at the start of work 
and remove it at the end of each day. Appropriate locker rooms that 
provide separate storage facilities for street, work and protective 
clothing shall be provided.
(c) Clothing contaminated with 4,4'-Methylenebis(2-chloroaniline) 
shall be removed and placed in a closed container in a well-ventilated 
area for later disposal or decontamination. Employers shall require 
personnel who work with 4,4'-Methylenebis(2-chloroaniline)„ to shower 
before leaving the workplace at the end of each workday.
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(d) Employers shall ensure that employees who handle 4,4'- 
Methylenebis(2-chloroaniline) wash their hands thoroughly with soap and 
water before eating, smoking, or using toilet facilities.
(e) The storage, dispensing, preparation, and consumption of food 
and beverages shall be prohibited in 4,4'-Methylenebis(2-chloroaniline) 
work areas. Also, smoking shall be prohibited in 4 , 4 '-Methylenebis(2- 
chloroaniline) work areas, and smoking or related materials, i.e., 
snuff or chewing tobacco, shall not be carried into such areas.
(f) The employer shall ensure that personnel who launder and clean 
clothing or equipment contaminated with 4,4'-Methylenebis(2- 
chloroaniline) are aware of the potential hazards of exposure.
Section 8 - Monitoring and Recordkeeping Requirements
(a) Requirements set forth below apply to work areas where there is 
occupational exposure to 4,4'-Methylenebis(2-chloroaniline).
(1) An adequate number of personal air samples shall be 
collected monthly for the evaluation of the work environment with 
respect to the occupational exposure of employees.
(2) Environmental samples shall be taken when a new process is 
installed or changes made that may cause an increase in environmental 
conentrations. Significant increases in production, relocation of 
existing operations, interruption of normal maintenance schedules, or 
other functions that may increase airborne 4,4'-Methylenebis(2- 
chloroaniline) concentrations shall require resampling and analysis 
until two consecutive samples collected at least 1 week apart
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demonstrate that the concentration is below the permissible exposure 
level.
(3) The minimum number of representative exposure 
determinations for an operation or process shall be based on variations 
in exposures and production schedules, and in accordance with the 
provisions prescribed in Section 1(b).
(4) If initial, periodic, or special evaluations indicate that 
the recommended permissible exposure level is exceeded, corrective 
engineering or other control measures shall be immediately instituted 
to ensure the safety of employees until a concentration below the 
recommended permissible exposure level is achieved. In such cases, 
sampling of each operation and work location shall be conducted until 
two consecutive employee exposure measurements, taken at least 1 week 
apart, reveal that the employee is not exposed to 4,4'-Methylenebis(2- 
chloroaniline) above the recommended permissible exposure level.
Routine monitoring may then be resumed. Employers shall notify in 
writing, within 5 days, every employee who is found to be exposed to 
4,4'-Methylenebis(2-chloroaniline) above the recommended permissible 
exposure level.
(b) Employers or their successors shall maintain records which 
shall include the sampling and analytical methods, and types of 
respiratory protection used, airborne concentrations found, and any 
additional information concerning exposure of employees to 4,4'- 
Methylenebis(2-chloroaniline). Each employee shall have access to data 
on his or her own environmental exposures. Pertinent records of 
occupational accidents and environmental exposures within the workplace
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shall be kept for at least 30 years after termination of employment. 
Records of occupational exposures applicable to an employee should be 
included in the employee’s medical records. These records shall be 
made, available to the designated representatives of the Secretary of 
Health, Education, and Welfare, of the Secretary of Labor, of the 
employee or former employee, and of the employer.
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A preliminary report concerning the carcinogenicity of orally 
introduced 4,4'-methylene-bis(2-chloroaniline)* in rats was made by 
Steinhoff and Grundmann [1] in 1969. In 1970 these two investigators 
published a more extensive paper [2] of their completed findings. In 
the later paper the toxicity and carcinogenicity of 4,4*-methylene- 
bis (2-chloroaniline) was compared with that of 4,4'- 
diaminodiphenylmethane (DDM). Both of these compounds are used as 
hardeners or curing agents for epoxy resin systems and isocyanate- 
containing polymers. [2, 4, 7] Although commercial production of
4,4'-methylene-bis(2-chloroaniline) began in 1962, [3] DDM has been in 
production for over 25 years. [4] The investigators quote previous 
work to document the strong toxic effect of DDM on both rat and human 
liver as well as the carcinogenic effect on rat liver. Schoental [4] 
has also demonstrated the carcinogenicity of DDM on the rat liver. An 
accidental acute poisoning episode occured in 1965 in Great
*4,4'-methylene-bis(2-chloroaniline) or 3,3'-dichloro-4,4'-
diaminodiphenylmethane has been given the registered trademark, MOCA, 
by the E. I. du Pont de Nemours & Co., Inc.
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Britain in which 84 persons became ill, some seriously, with jaundice 
following the consumption of bread accidentally contaminated with DDM. 
[5] In general, Steinhoff and Grundmann [1 and 2] considered 4,4'- 
methylene-bis(2-chloroaniline) to be less toxic but more carcinogenic 
than the non-chlorinated compound, DDM.
In their experiments Steinhoff and Grundmann [1 and 2] 
maintained fifty 100-day-old Wistar rats (25 male; 25 female) on a low 
protein diet containing 0.1 percent 4,4'-methylene-bis(2- 
chloroaniline) for 500 days. (Acute toxicity tests had earlier 
demonstrated the relative nontoxicity of the compound when all ten 
experimental animals in the study survived either an oral or a 
subcutaneous administration of a single dose of 5000 mg/Kg.) Control 
rats used in the chronic feeding experiment were maintained on an 
identical low protein diet excluding the test compound. At the 
termination.of the 500-day experimental feeding period (total dose of 
27 g/Kg body weight) the experimental animals were maintained on the 
control diet. The average life span for male rats was 565 test days, 
the average for females was 535 test days. The average life span for 
controls was 730 test days.
Of the 25 male animals, 23 died with tumors. Twenty-two animals 
had liver tumors and in 7 of these, primary lung tumors (not 
metastases) occured also. Two of the animals with liver tumors had 
lung metastases and one brain metastasy was observed. One animal 
without liver tumors exhibited "massive tumor permeation" of the lungs
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and benign bladder papillomas were observed in one animal. The two 
tumor-free animals exhibited fatty livers with isolated necrosis and 
hemorrhages.
Of the 25 female animals, 20 died with tumors. Eighteen animals 
had liver tumors and in 4 of these animals, three also had primary 
lung tumors (not metastases) and one had mammary gland tumors. Two 
animals had lung tumors without liver tumors and 9 had benign mammary 
gland tumors. The investigators emphasized that lung tumors in rats 
are relatively rare. Of the 50 control animals only two mammary 
fibroadenomas were observed in female rats, although the average life 
span of the controls was longer than that of the experimentáis.
In another set of experiments Steinhoff and Grundmann [6] 
injected a suspension of 94 percent pure, technical grade 4,4'- 
methylene-bis(2-chloroaniline) into 34 Wistar rats (17 males, 17 
females). Subcutaneous injections of 500 or 1000 mg/Kg body weight 
were administered on the order of once a week, or at longer intervals, 
to a total dose of 25 g/Kg body weight. Twenty-two of the 34 animals 
died with a total of 29 malignant tumors. Nine animals had liver cell 
carcinomas which, in all but one such animal, were discovered in 
multiple locations. Primary lung carcinomas were formed in 7 animals 
with a multi-central distribution in 3 animals. In the 50 control 
animals (25 males, 25 females) a total of 13 malignant tumors at 
different sites were discovered, including one lung tumor. No liver 
tumors developed over an average life span of 1040 days compared to an
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average life span of 778 days in experimentáis. The Investigators 
stated:
"Thus, SjS’-dichloro-A^’-diaminodiphenylraethane 
exhibits a definite carcinogenic action in the rat, the 
liver and lungs being the main organs affected, even 
after subcutaneous administration and sufficient 
protein nutrition. However, a greater number of liver 
tumors appear in a shorter time after feeding the 
compound in a low-protein diet."
In 1972, Sherman and Zapp [7] presented investigations in which 
rats fed a normal diet, but containing 1000 ppm of 4,4’-methylene- 
bis(2-chloroaniline) , for 18 months subsequently developed lung tumors 
with some spreading to the pleural cavity. The investigators also 
observed an increased incidence of liver tumors. When animals were 
maintained on a low protein diet containing the compound, the 
incidence and malignancy of both liver tumors (males) and mammary 
tumors (females) was found to Increase.
A contemporary paper by the National Cancer Institute reports on 
the work of the Weisburgers [8] concerning the carcinogenicity of 
A,4'-methylene-bis(2-chloroaniline) in mice and rats. Preliminary 
studies established the maximally tolerated dose of this compound in 
the diet was 1000 mg/Kg body weight in rats and 2000 mg/Kg body weight 
in mice. Control animals were maintained on Purina laboratory chow
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during the chronic feeding investigations while equal numbers of 
experimental animals (25 male mice; 25 female mice; 25 male rat?) were 
dosed at the above levels and other groups at half these levels. 
Tumors observed in experimental animals and absent in controls 
included: hepatomas in rats (4/19 effective rats at the high dose and
1/22 effective at the low dose); 1 glioma; 2 adenocarcinomas of the 
lung; 2 gastrointestinal adenocarcinomas; 1 ear duct tumor; 2 tumors 
of the urinary bladder; and 7 adenomata of the lung.
In female mice, hepatomas were observed in 50 percent of the 
animals at the high dose and 43 percent at the low dose. No hepatomas 
were observed in female control mice. In male mice there was no 
significant difference between experimentáis and controls concerning 
the incidence of hepatomas. Although no vascular tumors (hemangiomas 
and hemangiosarcomas) were found in control mice, such tumors were 
observed in 40 percent of the males and 43 percent of the females 
receiving the high dose. At the low dose 23 percent of the males and 
none of the females were observed to develop vascular tumors. 
Malignant lymphomas which were common in control mice were not as 
common in the experimental animals.
It is interesting that three Independent studies [6 through 8] 
have reported the development of lung tumors in rats exposed to 4,4'- 
methylene-bis(2-chloroanillne). As emphasized by the investigators of 
two of these studies, [6 and 8] the rat is not highly susceptible to 
lung tumor formation. The influence of diet is known to alter the
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carcinogenic potential of various substances and diet apparently 
affects the carcinogenic potential of 4 ,4'-methylene-bis(2- 
chloroaniline), but the results of two studies [7 and 8] in which the 
experimental animals were maintained on a normal diet, to which the 
test substance was added, clearly demonstrate that the effect of diet, 
alone, is not sufficient to account for the oncogenic activity of 4- 
4 ,-methylene-bis(2-chloroaniline).
A single plant cohort study involving a group of 31 employees 
and an equal number of controls was published by Linch et al [3] in 
1971. The length of exposure of the control group was not specified. 
When compared to the control group no significant findings were 
observed utilizing the Pap technique as a screening tool for the early 
identification of bladder cancer.
Medical records for 178 employees were reviewed for evidence of 
acute illnesses, specific systemic illnesses, chronic disease, and 
malignancy. With the exception of 4 individuals all individuals in 
this group had not been exposed to 4 ,4'-methylene-bis(2-chloroaniline) 
for the last 10 years. In this group the elapsed time since first 
exposure was:
a) less than 10 years - no employees
b) from 10 to 15 years - 158 employees
c) more than 15 years - 20 employees
If the assumption is made that, of the group of 158 employees, 15
years had elapsed since the first exposure, and that no exposure had
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occured for 10 years, then their total exposure was 5 years. 
Likewise, the total exposure of the group of 20 employees in which 
more than 15 years had elapsed since first exposure would be a maximum 
of approximately 2 years. Because of the short exposure durations of 
both groups, it should not be considered unusual that negative 
findings were reported since the known average latency period for 
development of occupational bladder cancer is approximately 20 years.
The fact that the rate of cancer deaths in the plant population 
was better than national cancer statistics is not surprising when 
consideration is given to the differences between the total U.S. 
population and the able working population of the plant.
These investigators considered the principal route of absorption 
to be other than respiratory and recommended biologic rather than air 
monitoring as the procedure of choice for exposure control.
Another industrial study involved the finding by Mastromatteo 
[9] in 1965 that two of six employees, both in their thirties, who had 
a mixed exposure to 4 ,4'-methylene-bis(2-chloroaniline), TD1 and 
several isocyanate-containing resins developed urinary frequency with 
hematuria in addition to eye irritation, respiratory irritation with 
cough and tightness in the chest. The hematuria can best be related 
to the 4 ,4,-methylene-bis(2-chloroaniline) than to the other 
substances. The author considered the conditions to be mild but also
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considered that exposure to this substance, primarily by dust 
inhalation, was the cause of the observed cystitis.
The results of the experimental animal studies involving rats 
and mice, as reported by three independent groups of investigators, 
[1,2,6,8] clearly demonstrate an active oncogenic role for 4,4'- 
methylene-bis(2-chloroaniline).
The absence of definitive industrial experience with only 2 
reported studies, [3 and 9] and the positive findings in two animal 
studies by 3 independent investigators, preclude the elimination of 
4,4,-methylene-bis(2-chloroaniline) as a human carcinogen.
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APPENDIX II
METHOD FOR SAMPLING AND ANALYSIS OF 4,4'-METHYLENEBIS 
(2-CHLOROANILINE) IN AIR
The NIOSH recommended methods for sampling and analysis of 4,4'- 
Methylenebis(2-chloroaniline) in air may be found in the NIOSH Manual 
of Analytical Methods (1) , and the NIOSH Manual of Sampling Data Sheets 
(2).
The recommended methodology utilizes a two stage sampler consisting 
of a high efficiency glass-fiber filter, followed by a bed of silica 
gel sorbent to collect 4,4'-Methylenebis(2-chloroaniline) aerosol and 
vapor, and a high performance liquid chromatograph (HPLC) equipped with 
a UV detector for analysis. This method has been evaluated at levels 
as low as 0.15 /xg per sample collected (50 1 of air at 3.0 /xg/m3) and 
found suitable (3).
While the recommended method is thought by NIOSH to be the best 
available at this time, it is still subject to further review and 
refinement. If research by NIOSH results in the development of 
improved methods for sampling and analysis of 4,4'-Methylenebis(2- 
chloroaniline) in air from the occupational environment, the 
information will be forwarded to the Department of Labor.
Monitoring for work surface contamination and for workers’ urinary 
4,4'-Methylenebis (2-chloroaniline)_ content should be routinely 
undertaken to supplement monitoring of workplace air. Industrial
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experience has indicated that huild-up of 4,4'-Methylenebis(2- 
chloroaniline) on workplace surfaces, even from low airborne levels may 
account for an increase of workers' urinary 4,4'-Methylenebis(2- 
chloroaniline) content above that which would normally be expected 
(15). Baseline data on individual workers' urinary 4,4'- 
Methylenebis(2-chloroaniline) content and for work surface 
contamination should be gathered under ideal working conditions, i.e., 
workers are provided with adequate protective clothing and equipment, 
work surfaces have been washed down (see Section 6 (f)), and airborne 
4,4'-Methylenebis(2-chloroaniline) concentrations are at or below the 
recommended permissible exposure level. Assuming that the recommended 
airborne level for 4,4'-Methylenebis(2-chloroaniline) is being met, 
detection of the chemical at levels above the baseline in either 
urinary monitoring or spot tests would indicate a need for improving 
work practices and for washdown of work surfaces. Analysis for urinary 
4,4'-Methylenebis(2-chloroaniline) content should be undertaken weekly 
at the end of the workshift. Spot tests should also be done on a 
frequent basis for the detection of work surface contamination and as 
confirmatory tests for unusual findings in urinary monitoring and 
following accidents, spills, leaks or any changes in the industrial 
process which might produce an increase in the accumulation of 4,4'- 
Methylenebis(2-chloroaniline)_ on workplace surfaces. Methodology for 
both spot tests and monitoring of urinary 4, 4 '-Methylenebis(2- 
chloroaniline) content have been developed and used successfully by 
LASL (17) and the DuPont Company (Appendix III and IV).
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APPENDIX III
METHOD FOR DETERMINATION OF MOCA (TM) IN URINE BY GAS CHROMATOGRAPHY*
I. Scope and Application
This is a method for the determination of low levels of 
methylenebis-(ortho-chloroaniline) (MOCA) in ethyl ether extracts 
of urine samples.
The method can also be used to measure the approximate 
concentration of LD-813 present in urine. The LD-813 level can be 
estimated by measuring the MOCA content and dividing the result by
0.4.
The method was developed using a Hewlett-Packard 5750 gas 


















II. Sensitivity, Precision, and Accuracy
The precision of this method at the 95% confidence limits, for ten 
degrees of freedom, is + 0.02 mg/liter at the Q.1 mg MOCA/liter 
urine level and + 0.14 mg/liter at the 0.5 mg MOCA/liter urine 
level. This precision was determined by two technicians on two 
separate days.
The lower limit of detection is 0.04 mg MOCA/liter of urine. This 
sensitivity was determined by adding decreasing amounts of MOCA to 
urine, extracting with ether, and analyzing.
Samples were prepared at 0.1 and 0.5 mg/liter levels on five 
separate days and analyzed. Accuracy was within the limits of the 
precision.
III. Safety Precautions
1. Ethyl ether is extremely flammable. Handle with care in a 
well-ventilated hood away from sparks and flames. The TLV is 400 
ppm.
*This method is one employed by E.I. duPont de Nemours and Company, Inc., 
Elastomer Chemical Department, Wilmington, Delaware 19898, and is identified 
by their Code No. U860.5200S, 30 July 1975.
2. Trifluoroacetic anhydride is a poisonous lachrymator. Avoid 
inhalation of vapors and skin contact. If spilled on the skin, 
flush immediately with copious quantities of cold water.
3. Chloroform is poisonous. It should be handled with adequate 
ventilation. Avoid repeated or prolonged contact with the skin. 
The TLV is 25 ppm.
4. Ethyl alcohol is a flammable material. Handle in a well-
ventilated hood away from sparks and flames. The TLV is 100 ppm.
5. Handle triphenylamine with care as it is an aromatic amine. 
Keep off skin; handle in well-ventilated area.
6 . MOCA is a "cancer-suspect agent" and is regulated by the
Department of Labor, Occupational Safety and Health
Administration's "Carcinogens - Occupational Health and Safety 
Standards." As required by this Standard, the following are 
posted at the regulated area: definition of the regulated area,
handling procedures, decontamination procedures, waste disposal, 
emergency procedures, regulated area entry log sheets, and 
inventory log sheets. Only those persons specifically designated 
to work with MOCA are allowed to enter the regulated area.
7. The volumetric flask used in the preparation of MOCA standard 
solution must be charged with MOCA inside the designated hood 
area. For weighing purposes the flask must be decontaminated with 
acetone prior to removal from the hood. Dispose of 
decontamination rinsings into containers approved for this 
purpose.
TV. Reagents
1. Chloroform, reagent grade
2. Ethyl ether, anhydrous ACS grade
3. Trifluoroacetic anhydride, Eastman white label No. 7386**
4. Triphenylamine, Eastman white label No. 1907
5. Trisodium phosphate, 1% aqueous solution
6 . Nitric acid, 1 + 1 .
7. Citric acid, 30% aqueous solution
8 . Ethyl alcohol, absolute, U.S.P.
9. Triphenylamine Internal Standard Solutions
**The mentioning of product names does not constitute endorcement by the Department 
of Health, Education, and Welfare.
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a. Internal Solution A
1) Weigh (to the nearest 0.0001 g) 0.045 - 0.055 g 
triphenylamine (TPA) into a 100-ml volumetric flask.
2) Dilute to volume with chloroform and mix.
3) Calculate TPA concentration as follows:
Cone TPA Solution A, /ug/ml - wt TPA, g x 10,000
b. Internal Solution B
1) Add (pipet) 4.0 ml of TPA Standard Solution A to a
100-ml volumetric flask.
2) Dilute to volume with chloroform and mix.
3) Calculate TPA concentration as follows:
Cone TPA Solution B, Mg/ml = Cone TPA Solution A x  0.04
10. MOCA Standard Solutions (See Safety Precautions, Section III)
a. MOCA Standard Solution A
1) Weigh (to the nearest 0.0001 g) 0.0045 - 0.0055 g of MOCA 
into a 100-ml volumetric flask.
2) Dilute to volume with ethyl alcohol and mix.
3) Calculate MOCA concentration as follows:
Cone MOCA Solution A, ¿tg/ml = wt MOCA, g x 10,000
b. MOCA Standard Solution B
1) Add (pipet) 10 ml of MOCA Standard Solution A  to a 
100-ml volumetric flask.
2) Dilute to volume with ethyl alcohol and mix.
3) Calculate MOCA concentration as follows:
Cone MOCA Solution B, Mg/ml = Cone MOCA Solution A x 0.1 
Note: MOCA Solution B contains approximately 5 jug/ml
c. MOCA Standard Solution C
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1) Add (pipet) 50 ml of MOCA Standard Solution A to a 
100-ml volumetric flask.
2) Dilute to volume with ethyl alcohol and mix.
3) Calculate MOCA concentration as follows:
Cone MOCA Solution C, jug/ml = Cone MOCA Solution 
A x 0.5
11. Sodium bicarbonate, 10% aqueous
12. Brilliant Yellow indicator strips
13. MOCA recrystallized to a 109 C minimum melting point
V. Apparatus
1. Bottles, specimen, milk dilution plain, Corning No. 1365
2. Caps, gum rubber, Davol "Sani-Tab" No. 268, 1-1/2 in. od
3. Separatory funnel, Squibb, 125-ml with TEFLON(TM) stopcock
Clean all glass apparatus by soaking for a minimum 
of one hour, preferably 16 hours, in .1% aqueous trisodium 
phosphate. Rinse with distilled water, 1 + . 1  nitric acid, 
and distilled water.
V I . Column Packing
Partitioning liquid OV-1
Source Supelco, Inc., Beliefonte, Pa.
Parts by weight liquid per 
100 parts support 11.1%
Support Supelcoport
Source Supelco, Inc., Bellefonte, Pa.
Mesh size 80 - 100
This column packing is sold commercially by Supelco, Inc., Supelco 
Park, Bellefonte, Pa. 16823
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Injection port temperature 
Sample size
5 ft x 0.085 in. (id)





























Any material having a chromatographic elution time identical to 
the MOCA derivative will yield high results. High MOCA analyses 
have been reported by individuals under medication at the time of 
sampling. Some medications interfere grossly with the 
determination. Each medication should be studied individually for 
its possible interference with this determination. The following 
medications have been evaluated.
Gross Interference Slight Interference No Interferences
Darvon (TM) Talwin (TM) Ananase (TM)









Effects of inhalation or ingestion of industrial chemicals upon 
this determination are not known. Some indication of possible 
interference can be obtained by adding the known chemical to human 
urine and analyzing the sample according to the method. This 
procedure, however, does not take into account any possible 
metabolite of the chemical under study. Materials tested under 
these conditions and found to produce chromatographic peaks in the 
MOCA derivative region and possibly interfere include HVA-2,
POLYAC, and ZENITE. The following do not interfere: ADIPRENE, A-
101 oil, Diak 3, Glycol E, HYLENE MP, HYLENE W, Micro-cel E, NA- 
22, PACM, VITON, HYLENE TRE, IML-1, CAYTUR 4, 




1. Clean all glassware as directed in Section V, Apparatus.
2. To the clean specimen bottle, add (grad cyl) 2 ml of 30% citric 
acid stabilizer solution. Seal the bottle with the "snap-on" 
rubber cap.
3. After the urine specimen has been placed in the bottle, seal the 
bottle with the cap as quickly as possible. Mix the solutions by 
swirling.
The urine solution can be stored for several hours in 
its stabilized form; however, the time should be kept 
as short as possible to prevent degradation of the 
MOCA. See Section XII, Calibration for degradation 
rate of MOCA in stabilized urine.
4. Add (grad cyl) 50 ml stabilized urine sample to the 125-ml
separatory funnel.
Start standard by adding 1 ml of MOCA Standard Solution B 
to 50 ml of uncontaminated urine; swirl to mix and let 
stand 5 min.
5. Add (pipet) 10 ml of ethyl alcohol and shake to mix. Let
solution stand 5 min.
6 . Add (grad cyl) 5 ml of 10% sodium bicarbonate solution and
shake to mix, venting the C02 through the stopcock.
7. Test the urine with Brilliant Yellow indicator paper. If the
solution is not definitely alkaline, add additional 1-ml
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increments of bicarbonate until a positive test is obtained.
Brilliant Yellow paper changes to a bright red color 
in an alkaline medium.
8 . Add 50 ml ethyl ether and shake steadily for 2 min.
Do not use intermittent shaking as an emulsion will 
result.
9. Let the solutions stand for 5 min to permit complete phase 
separation. Drain off the lower urine layer and discard.
10. Swirl the funnel to clear the interface and remove the last few 
ml of urine
11. Add (grad cyl) 5 ml of 10% sodium bicarbonate solution; shake 
for 10 sec (venting through the stopcock).
12. Let the solutions settle for 5 min and drain off the bottom 
layer.
B. Analysis for MOCA
1. Drain ether layer into a 30- x 80-mm vial. Evaporate the ether 
to dryness by blowing a stream of dry nitrogen into the vial.
Do not use air to evaporate the ether. A hot water 
bath may be used to hasten evaporation.
2. Add (medicine dropper) 1 ml trifluoroacetic anhydride. Allow the 
materials to react for a minimum of 10 min at room temperature.
3. Evaporate the contents of the vial to dryness using dry nitrogen.
4. Add (pipet) 1.0 ml TPA internal Standard Solution B and mix
thoroughly.
5. Inject 3-/ul samples into the chromatograph. (See Figure I)
Before analyzing any urine samples, condition the column 
by injecting several 6-/ul samples of MOCA standard sample F. 
Preconditioning of the column is necessary to minimize 
adsorption and loss of MOCA.
X. Calculations
1. Determine the areas for MOCA and TPA using the formula:
Peak area, mm2 = peak height x width at 1/2 height x attenuation
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2. Calculate the area ratio for MOCA
Area ratio MOCA = area MOCA mm2
area TPA mm2
3. Determine the weight ratio for MOCA from the calibration curve, 
Figure II. (See Section XII, A.)
4. Calculate ¡ig MOCA as follows:
MOCA, Mg = wt ratio MOCA x conc TPA Soln, /ug/ml
MOCA extracted, mg/liter = jLtg MOCA
ml sample
5. Correct MOCA concentration for extraction efficiency as follows:
MOCA, mg/liter = MOCA extracted, mg/liter x Reciprocal Extraction 
Factor, see Figure III.
Report results to nearest 0.01 mg/liter.
XI. Column Standardization
Inject a sample which has been prepared according to the procedure 
(Section IX). Each peak must have the approximate retention time 
(+ 5%), shape, and degree of resolution as those in a standard 
chromatogram. If these requirements are not met, check the 
operating conditions and/or replace the column.
XII. Calibration
A. Calibration Curve
1. Preparation of MOCA Stock Solution 1 (See Safety Precautions, 
Section III)
a. Weigh (to the nearest 0.0001 g) 0.045 - 0.055 g MOCA into
a 100-ml volumetric flask.
b. Dilute to volume with ethyl ether.
c. Calculate MOCA concentration as follows:
Conc MOCA Soln 1, ng/ml = wt MOCA, g x 10,000
2. Preparation of MOCA Stock Solution 2
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a. Pipet 10 ml MOCA Stock Solution 1 into a 1-liter volumetric 
flask.
b. Dilute to volume with ethyl ether.
c. Calculate MOCA concentration as follows:
Cone MOCA Soln 2, ng/ml = conc Soln 1, /ig/ml x 0.01
3. Preparation of Standard Samples
a. Into five 30- x 80-mm vials, add (pipet) MOCA Stock Solution 2 
as shown below:
Standard Sample MOCA Stock Solution 2
A  0.4 ml ( approximately 2 jug)
B 1.0 ( approximately 5 Mg)
C 2.0 ( approximately 10,jug)
D 3.0 ( approximately 15 Mg)
E 4.0 ( approximately 20 jug)
F 5.0 ( approximately 25 Mg)
b. Evaporate the standard samples to dryness under a nitrogen 
blanket. A water bath at 40 C may be used to aid evaporation.
c. Add (pipet) 1 ml trifluoroacetic anhydride and allow to react 
for 10 min.
d. Evaporate to dryness under a nitrogen blanket.
e. Add (pipet) 2 ml of triphenylamine Stock Solution B to each 
of the five standard samples.
f. Calculate weight ratio of MOCA/TPA in each standard sample, 
using the formula:
Wt ratio MOCA/TPA = Conc MOCA Soln 2 x vol Soln 2 added, ml
Conc TPA Soln x 1 ml
4. Preparation of Calibration Curve
a. Inject 3~m 1 sample of each standard sample into the chromat­
ograph. Condition the column before injecting any samples 
(see Note 1).
b. Measure peak areas of MOCA derivative and TPA using formula:
Peak area mm2 = peak height x width at .1/2 height x attenuation.
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c. Calculate area ratio of MOCA derivative and TPA as shown:
Area ratio MOCA = area MOCA mm2
area TPA mm2
d. Plot area ratio versus weight ratio for MOCA and draw a curve 
through the points. (See Figure II.)
B. Extraction Factor
1. Preparation of MOCA/Urine Solutions
a. Add (grad cyl) 50 ml of stabilized, uncontaminated urine to 
20 separatory funnels.
b. Add (pipet) 1 ml of MOCA Standard Solution B to each of 10 
funnels and 1 ml (pipet) of MOCA Standard Solution C to the 
other 10.
c. Swirl to mix and let stand 5 min.
2. Preparation of Extraction Curve
a. Proceed starting from Section IX, A, step 5.
b. Determine mg/liter MOCA extracted from Section X, Calculation.
c. Calculate Reciprocal Extraction Factor as follows:
Reciprocal Extraction Factor = /jg/ml MOCA Standard Soln x 1 ml
mg MOCA Extracted
d. Average Extraction Factors for each solution.
e. Plot mg/liter MOCA Extracted versus Extraction factors and draw
a curve through the points. (See Figure III.)
C. Degradation Rate
1. Preparation of MOCA/Urine Solutions
a. Add (grad cyl) 50 ml of stabilized, uncontaminated urine to 
14 specimen bottles.
b. Into seven bottles, add 1 ml of MOCA Standard Solution B and
into the other seven add 1 ml of MOCA Standard Solution C.
c. Swirl to mix and store at room temperature
d. Analyze for MOCA, mg/liter on 1,2,3,4,5,9, and 13 days, starting
with Section IX, A, step 5.
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2. Preparation of Degradation Curve
a. Plot MOCA, mg/liter versus time and draw a curve through the 
points. (See Figures IV and V.)
XIII. Notes
1. Condition the column daily by injecting several 6-^1 samples of MOCA 
derivative from standard sample F. The column must be conditioned 
before any urine samples are run for MOCA content.
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RECIPROCAL EXTRACTION FACTOR 
Figure 3 .  Extraction efficiency factor for MOCA in urine.
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Figure 5 .  Moca in urine degradation rate at room temperature 
0.1 m g /lite r  level .
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APPENDIX IV.
METHOD FOR DETECTION OF MOCA (TM) CURING AGENT ON ENVIRONMENTAL 
SURFACES BY COLORIMETRIC SPOT TEST*
I. Scope and Application
This colorimetric method is applicable to the detection of MOCA on 
environmental surfaces and on protective clothing in the absence 
of other primary aromatic amines. The method is simple and can be 
readily used in the field.
II. Principle
The method is based upon the formation of a color complex by the 
reaction of the amine group of MOCA with nitrous acid to form the 
diazonium salt and subsequent coupling with itself. The nitrous 
acid is prepared "in situ" by reacting an aqueous solution of 
sodium nitrite with acetic acid.
III. Interferences
This method is a general colorimetric spot test for primary 
aromatic amines and not specific for MOCA.
Environmental surfaces and protective clothing may be contaminated 
with material which is colored originally. A positive test is one 
in which color is formed or increased after addition of the last 
reagent.
IV. Sensitivity, Precision, and Accuracy
The lower limit for the detection of MOCA using the colorimetric 
spot test was determined by swabbing an 0.05 sq. meter stainless 
steel area. Solutions of decreasing concentrations of MOCA were 
evaporated off the tray. The tray was then swabbed. The lower 




VI. Reagents (Reagent Grade).
1. Dimethylformamide (DMF)
2. Acetic acid
*This method is one employed by E.I. duPont de Nemours and Company, Inc., 
Elastomer Chemical Department, Wilmington, Delaware 19898, and is identified 
by their Code No. E350.5200S, 15 March 1976.
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3. "Nitrite" solution
Dissolve 20 g sodium nitrite in 100 ml distilled water.
VII. Safety Precautions
1. DMF is rapidly absorbed through the skin and can carry other chemicals
into the skin. DMF can pave the way for dermatitis. DMF is classified
as a teratogen and females of childbearing age should not work with 
this chemical. If DMF comes in contact with the skin, wash well with 
water immediately.
2. Reagent grade acetic acid can cause serious burns and blisters to the 
skin. Wash well with water immediately if acetic acid is spilled on 
the skin.
3. MOCA may cause cancer based on tests with laboratory animals. Avoid
skin contact and inhalation of vapor and dust. For details on safe
handling practices, read bulletin AP 710.1.
VIII. Procedure
1. Place 10 ml of DMF in a glass vial.
2. Place a cotton swab into the glass vial containing DMF.
3. Wait 30 sec.
4. Wipe an area 8 in. x 10 in, with the cotton swab. Go over the area
three times.
5. Place the cotton swab back into the DMF.
6 . Wait 30 sec.
7. Add approximately 1 ml of acetic acid to the vial.
8 . Add approximately 1 ml of "nitrite" solution to the vial.
9. Observe solution for development of an orange-brown color. The color 
which forms within 1 minute indicates that MOCA may be present
(see Note 1).
IX. Notes
1. If the solution has color after swabbing, it is advisable to obtain
two swabs of the same area (adjacent locations). One vial acts as a 
blank and compensates for any color pickup due to swabbing. The blank 
is treated exactly the same as the sample vial except that nitrite 
solution is not added. The two vials can be viewed side by side; any
color increase in the nitrite treated sample can he easily noted.
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A  quantitative method for detection of certain carcinogens on metal, 
painted and concrete surfaces has been developed by Weeks, R.W. Jr., 
Dean, B.J. and Yasuda, S.K. and has been published in Analytical 
Chemistry Vol 48: 2227-2233, 1976.
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